Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation develops high-performance scientific instruments and analytical and diagnostic solutions for life science, applied, biopharma, microscopy, nanoanalysis, industrial, cleantech and semiconductor metrology markets.
Recurring news for BRKR includes earnings updates for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, product launches across NMR, microbiology, infection diagnostics, spatial biology and AFM-IR spectroscopy, and governance changes. Company announcements also cover platforms such as MALDI Biotyper, IR Biotyper, MyGenius PRO, GeoMx, CellScape, CosMx and Dimension IconIR.
Bruker Corporation (NASDAQ: BRKR) has announced the appointment of Philip Ma, Ph.D., to its Board of Directors, effective April 1, 2022. Dr. Ma is the CEO and founder of PrognomiQ and has significant experience in life sciences, particularly in multiomics and cancer diagnostics. His previous roles include leadership positions at Biogen and McKinsey & Company. The company aims to leverage his expertise to advance its Project Accelerate 2.0 initiatives, which focus on enhancing life science and clinical research tools.
Bruker Corporation (NASDAQ: BRKR) announced enhanced capabilities for its Fourier 80 benchtop FT-NMR spectrometer, now featuring an Adjustable Temperature option for samples between 25°C to 60°C. This upgrade expands applications in pharmaceutical and food analysis, improving synthesis and process control. The introduction of the RxnLab™ solution offers temperature-controlled monitoring of reactions, while the Olive Oil-Profiling™ 1.0 solution supports olive oil authenticity analysis. The enhancements aim to elevate research capabilities in various analytical laboratories.
Canopy Biosciences, a Bruker Company, launched the CellScape™ System, enhancing ChipCytometry technology for high-plex spatial proteomics. This new benchtop system improves automation, optical performance, and throughput, enabling researchers to analyze millions of cells with single-cell resolution. Since the 2020 acquisition by Bruker, Canopy has advanced its capabilities, setting a new standard in spatial biology research. The CellScape™ is designed for large-scale clinical studies and is compatible with standard fluorescently labeled antibodies, fostering streamlined workflows in immunology and other fields.
Bruker Corporation (NASDAQ: BRKR) and Newomics Inc. announced a co-marketing collaboration focused on a novel LC-MS platform for drug discovery in pharma and biopharma. The partnership will integrate Newomics’ Microflow-nanospray Electrospray Ionization (MnESI) products with Bruker’s mass spectrometers, enhancing isotopic fidelity and sensitivity for biological sample analysis. Both companies highlight their successful R&D collaborations and the potential for improved results in biopharmaceutical and clinical research.
Summary not available.
Bruker Corporation (Nasdaq: BRKR) will participate in Cowen’s 42nd Annual Health Care Conference from March 7-9, 2022. Gerald Herman, Executive VP & CFO, will present on March 7, 2022, at 2:50 PM EST. A live webcast of the presentation will be accessible on the Company’s Investor Relations website, with a replay available for 90 days post-event. Bruker specializes in high-performance scientific instruments and solutions that enhance life sciences and diagnostics, empowering scientific breakthroughs.
Bruker Corporation has announced an increase in its quarterly cash dividend to $0.05 per share, up from $0.04 in Q1 2021. The new dividend will be paid on March 18, 2022, to stockholders of record as of March 1, 2022. Furthermore, the Board has approved a plan to raise its annual cash dividend from $0.16 to $0.20, contingent on quarterly Board approval beginning with this payment.
Bruker Corporation (Nasdaq: BRKR) reported Q4 2021 revenues of $683.5 million, an increase of 8.9% year-over-year, with organic growth of 11.4%. FY 2021 revenues reached $2.42 billion, up 21.7%, with non-GAAP EPS rising 55.6% to $2.10. For FY 2022, Bruker expects revenue growth between 5% to 7%, and non-GAAP EPS guidance of $2.29 to $2.33, reflecting solid performance despite ongoing supply chain challenges. Significant investments in Project Accelerate 2.0 focus on proteomics and spatial biology are expected to drive future growth.
Bruker Corporation (Nasdaq: BRKR) will participate in the 11th Annual SVB Leerink Global Healthcare Conference virtually on February 16, 2022, at 8:40 AM EST. Frank Laukien, Chairman, President & CEO, will represent the company. Interested parties can access a live audio webcast on the Investor Relations section of Bruker's website. A replay will be available for 30 days post-event. Bruker specializes in high-performance scientific instruments and solutions for life sciences and diagnostics, contributing to advancements in molecular and cellular research.
Bruker Corporation (Nasdaq: BRKR) unveiled its innovative Sierra SPR-32 Pro at the SLAS2022 International Conference, enhancing high-throughput screening (HTS) capabilities. This advanced microfluidic system allows parallel readout of 32 sensor spots, significantly expediting drug development by reducing measurement time by up to threefold. The system is ideal for characterizing biologics and small molecules, supporting complex assays with high sensitivity. Bruker's integration with automation and data transfer to analysis software streamlines research processes for drug discovery.